Drug discovery is full of false starts, and a big part of the problem is the disconnect between our models and real human biology. With immortalized cell lines, researchers often find that their promising compounds don't behave the same way in primary cells or in vivo. That’s why human induced pluripotent stem cell (iPSC)-based disease models have moved from niche innovation to mainstream application.

Despite their initial novelty, iPSCs are now a go-to tool for building more predictive, human-relevant assays in drug discovery workflows. So, if you’re not using them yet, there’s a good chance you’ll be analyzing data from them soon.

Why iPSC models are gaining traction

Stem cell disease modeling offers three clear advantages that make it a powerful tool across research and early-stage drug development:

• Patient specificity: Because iPSCs carry the donor’s genome (including disease-associated mutations), they enable direct modeling of rare or complex diseases in human cells¹.

• Human relevance: Differentiated iPSC-derived neurons, cardiomyocytes, hepatocytes, and others recapitulate key functional aspects of real tissue: synaptic activity, contractility, and metabolic capacity respectively².

• Scalability: Once a differentiation protocol is locked in, iPSC lines can be expanded indefinitely and manufactured at the scale required for screening³.

This makes them especially attractive for researchers trying to bridge the gap between high-throughput assays and meaningful clinical predictions. They’ve already become a standard in cardiac safety screening and are gaining traction in neurodegeneration and metabolic disorders.

Stem cell modeling across research areas

Because of their advantages, iPSC workflows are increasingly being developed and validated across industry and academia.

Neurodegeneration

iPSC-derived neurons from patients with Alzheimer’s, Parkinson’s, and ALS are used to model disease phenotypes like tau aggregation, mitochondrial dysfunction, or motor neuron degeneration. These cultures support phenotypic screens that have identified compounds capable of rescuing neuronal function in vitro^4,5.

Cardiotoxicity

iPSC-derived cardiomyocytes are now used routinely to screen for drug-induced arrhythmia risk. They’ve been integrated into regulatory safety initiatives like CiPA and are used by companies like Roche and Takeda for preclinical cardiac profiling^6,7.

Metabolic disease

Hepatocyte-like cells derived from iPSCs have been used to model familial hypercholesterolemia and test potential lipid-lowering therapies. In one example, they revealed a drug repurposing opportunity when cardiac glycosides reduced ApoB secretion⁸.

In each research area, the iPSC system offered something that cell lines and animal models couldn’t: an assay platform that’s reproducible, scalable, and human-relevant.

Why iPSCs are replacing immortalized lines

You don’t have to be a stem cell biologist to appreciate this shift. If you've worked with cancer-derived lines like HeLa, HepG2, or SH-SY5Y, you've seen how unpredictable or non-physiological they can be. They’re easy to grow, but they don’t model human disease very well. In contrast, iPSC-derived cells:

• Maintain the donor’s genotype⁹

• Often demonstrate complex functional behaviors (like beating or synaptic firing) that immortalized lines can't replicate

In short, they behave more like the cells you're actually trying to treat. And for pharma teams racing to develop new treatments, that’s no longer a nice-to-have—it’s a requirement.

High-throughput discovery

iPSC-derived cells aren’t just biologically relevant, they’re also compatible with high-throughput screening. You can plate them in 384- or 1536-well formats, image them automatically, and extract rich phenotypic data at scale³.

iPSC-based models are already being used in industrial phenotypic screens to identify new drugs, predict toxicity, and uncover mechanisms of action. Using high-content imaging, researchers can quantify changes in cell morphology, protein localization, or organelle health across thousands of wells. With the help of machine learning, this data is analyzed in bulk to identify compounds that reverse disease features, even when the target isn’t known.

The challenges of stem cell disease modeling

Of course, these systems come with challenges:

• Differentiation variability: Not all iPSC lines behave the same, and maturity can vary by lab or batch. Many protocols still yield cells with fetal-like phenotypes¹⁰.

• Cost: Media, reagents, and culture time can add up quickly. For HTS-scale assays, cost and throughput remain limiting for some groups.

• Standardization: Protocols for iPSC culture and differentiation are improving, but still not uniform. Efforts to benchmark electrophysiological performance or gene expression signatures are underway, but not universal¹¹.

That said, these challenges are being addressed. Commercial cell providers offer QC-verified batches, bioreactors, and automation are bringing down costs, and regulatory buy-in has given the field momentum.

A new path to discovery

Stem cell disease modeling isn’t replacing all other systems, but it is changing what “good data” looks like. When you can work with cells that mimic patient physiology, your readouts mean more. You get clearer signals earlier in the pipeline and fewer surprises down the road.

This opens up new opportunities for researchers to design smarter, more translational experiments. Whether you're studying ion channel disorders, screening neuroprotective compounds, or characterizing disease phenotypes, stem cell models let you bring human biology to the bench.

References

1.  Kim, E.; Kim, A.; An, J.; Kim, B.; Kim, S.; Lee, S.; Kim, E.; Lee, J.; Woo, D. Exploring Potential Applications of iPSC-Derived Cell Models for Drug Screening of Specific Diseases. Cytotherapy 2025, 27 (5, Supplement), S235. https://doi.org/10.1016/j.jcyt.2025.03.483.

2. Zhang, H.; Thai, P. N.; Shivnaraine, R. V.; Ren, L.; Wu, X.; Siepe, D. H.; Liu, Y.; Tu, C.; Shin, H. S.; Caudal, A.; Mukherjee, S.; Leitz, J.; Wen, W. T. L.; Liu, W.; Zhu, W.; Chiamvimonvat, N.; Wu, J. C. Multiscale Drug Screening for Cardiac Fibrosis Identifies MD2 as a Therapeutic Target. Cell 2024, 187 (25), 7143-7163.e22. https://doi.org/10.1016/j.cell.2024.09.034.

3. Soutar, M. P. M.; Carbone, B.; Kindalova, P.; Mehrizi, R.; Lopes, F. M.; Lam, N.; Rockliffe, A.; Braybrook, T.; Taylor, M.; Nguyen, C.; Ducotterd, F.; Reith, A. D.; Mohamet, L.; Plun-Favreau, H. A CRISPR-CAS9 High Throughput Machine-Learning Platform for Modulation of Genes Involved in Parkinson’s Disease-Associated PINK1-Mitophagy in iPSC-Derived Dopaminergic Neurons. bioRxiv June 15, 2025, p 2025.06.10.658840. https://doi.org/10.1101/2025.06.10.658840.

4. Barak, M.; Fedorova, V.; Pospisilova, V.; Raska, J.; Vochyanova, S.; Sedmik, J.; Hribkova, H.; Klimova, H.; Vanova, T.; Bohaciakova, D. Human iPSC-Derived Neural Models for Studying Alzheimer’s Disease: From Neural Stem Cells to Cerebral Organoids. Stem Cell Rev. Rep. 2022, 18 (2), 792–820. https://doi.org/10.1007/s12015-021-10254-3.

5. Salazar, A. iPSC-Based Neuromuscular and Neuronal Models for ALS and Drug Discovery. News-Medical. https://www.news-medical.net/whitepaper/20240916/iPSC-Based-Neuromuscular-and-Neuronal-Models-for-ALS-and-Drug-Discovery.aspx (accessed 2025-06-30).

6. Konala, V. B. R.; Kuhikar, R.; More, S.; Gossmann, M.; Lickiss, B.; Linder, P.; Sarkar, J.; Bhanushali, P.; Khanna, A. CiPA-Qualified Human iPSC-Derived Cardiomyocytes: A New Frontier in Toxicity Testing by Evaluating Drug-Induced Arrhythmias. Toxicol. In Vitro 2025, 108, 106100. https://doi.org/10.1016/j.tiv.2025.106100.

7. Blinova, K.; Stohlman, J.; Vicente, J.; Chan, D.; Johannesen, L.; Hortigon-Vinagre, M. P.; Zamora, V.; Smith, G.; Crumb, W. J.; Pang, L.; Lyn-Cook, B.; Ross, J.; Brock, M.; Chvatal, S.; Millard, D.; Galeotti, L.; Stockbridge, N.; Strauss, D. G. Comprehensive Translational Assessment of Human-Induced Pluripotent Stem Cell Derived Cardiomyocytes for Evaluating Drug-Induced Arrhythmias. Toxicol. Sci. 2017, 155 (1), 234–247. https://doi.org/10.1093/toxsci/kfw200.

8. Cayo, M. A.; Mallanna, S. K.; Furio, F. D.; Jing, R.; Tolliver, L. B.; Bures, M.; Urick, A.; Noto, F. K.; Pashos, E. E.; Greseth, M. D.; Czarnecki, M.; Traktman, P.; Yang, W.; Morrisey, E. E.; Grompe, M.; Rader, D. J.; Duncan, S. A. A Drug Screen Using Human iPSC-Derived Hepatocyte-like Cells Reveals Cardiac Glycosides as a Potential Treatment for Hypercholesterolemia. Cell Stem Cell 2017, 20 (4), 478-489.e5. https://doi.org/10.1016/j.stem.2017.01.011.

9. iPSC Neurons: Current Advances and Potential Applications. Biology Insights. https://biologyinsights.com/ipsc-neurons-current-advances-and-potential-applications/ (accessed 2025-06-30).

10. Lu, Y.; Liu, Y.; Yan, Y.; Fooladi, S.; Qyang, Y. Advancements in Techniques for Human iPSC-Derived Cardiomyocytes Maturation: Mechanical and Electrical Stimulation Approaches. Biophys. Rev. 2025, 17 (1), 169–183. https://doi.org/10.1007/s12551-024-01267-6.

11. Lyra-Leite, D. M.; Gutiérrez-Gutiérrez, Ó.; Wang, M.; Zhou, Y.; Cyganek, L.; Burridge, P. W. A Review of Protocols for Human iPSC Culture, Cardiac Differentiation, Subtype-Specification, Maturation, and Direct Reprogramming. STAR Protoc. 2022, 3 (3), 101560. https://doi.org/10.1016/j.xpro.2022.101560.